1. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study.
- Author
-
Sakanaka, K., Ishida, Y., Fujii, K., Ishihara, Y., Nakamura, M., Hiraoka, M., and Mizowaki, T.
- Subjects
- *
CISPLATIN , *CLINICAL trials , *CONFIDENCE intervals , *DRUG dosage , *DRUG side effects , *DRUG toxicity , *ESOPHAGUS diseases , *ESOPHAGEAL tumors , *FLUOROURACIL , *RADIATION doses , *SQUAMOUS cell carcinoma , *SURVIVAL analysis (Biometry) , *RADIATION pneumonitis , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *CHEMORADIOTHERAPY ,CHEST tumors - Abstract
About 80% of cases of locally advanced unresectable thoracic oesophageal squamous cell carcinoma recur within the irradiation fields after chemoradiotherapy. Radiation dose escalation using advanced radiotherapy techniques is expected to improve clinical outcomes by reducing local and regional recurrence. The current study aimed to determine the recommended escalated radiation dose for these patients. Patients with locally advanced unresectable thoracic oesophageal squamous cell carcinoma with good performance status underwent chemoradiotherapy using simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) with elective nodal irradiation. SIB-IMRT was delivered in five fractions per week. The radiation dose to the unresectable gross tumour was escalated from 66 Gy to a planned maximum dose of 72 Gy in 3 Gy increments in a standard 3 + 3 design. The doses to the resectable component, superficial tumours and elective nodal regions were fixed as 60, 51 and 48 Gy, respectively. Cisplatin and 5-fluorouracil were concurrently administered. Dose-limiting toxicity (DLT) was defined as acute grade 3 oesophagitis, grade 2 pneumonitis, grade 2 cardiac toxicity and a failure to complete planned radiotherapy within 60 days. Locoregional control and overall survival were estimated using the Kaplan–Meier method. Nine patients were enrolled. DLTs occurred in one of six and two of three patients at doses of 66 and 69 Gy, respectively. All DLTs were grade 3 oesophagitis. The recommended dose was determined as 66 Gy delivered in 30 fractions based on the predefined criteria. With a median follow-up period of 23 months, the 1-year locoregional control and overall survival rates were 67 (95% confidence interval = 19–90) and 78% (95% confidence interval = 36–94), respectively. The recommended radiation dose in chemoradiotherapy using SIB-IMRT with elective nodal irradiation was 66 Gy delivered in 30 fractions. • Recommended radiation dose in CRT using SIB-IMRT with ENI was 66 Gy in 30 fractions. • Oesophagitis is a major dose-limiting toxicity. • The results are consistent with reported dose-volume metrics of the oesophagus. • Omitting ENI is probably needed for a further dose escalation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF